Literature DB >> 29375010

Aggressive systolic blood pressure control in older subjects: benefits and risks.

Steven G Chrysant1.   

Abstract

Systolic hypertension, especially isolated systolic hypertension (ISH) is very common in older subjects aged ≥ 65 years and is a major risk factor for cardiovascular disease (CVD), strokes, heart failure (HF) and chronic kidney disease (CKD). It is also, directly and linearly related with these complications irrespective of sex, or ethnicity, but it is worse with the advancement of age. Effective control of systolic blood pressure (SBP), is associated with significant reduction in the incidence of these complications. Currently, there is a debate about the optimal SBP control in view of the Systolic Blood Pressure Intervention Trial (SPRINT) showing beneficial cardiovascular (CV) effects of intensive SBP of < 120 mmHg in older patients. Also, the recently released blood pressure (BP) guidelines by the American College of Cardiology, the American Heart Association and the American Society of Hypertension (ACC/AHA/ASH) recommend a SBP reduction of < 130 mmHg. These SBP treatment recommendations are in contrast with the current (JNC VIII) committee of BP treatment guidelines, which recommend a SBP reduction < 150 mmHg for the same age of patients. All these different recommendations have created a debate regarding the optimal treatment targets for the systolic hypertension of the elderly patients. To gain more information a focused Medline search was conducted from 2010 to 2017 using the terms, systolic blood pressure, aggressive control, older subjects, treatment guidelines, and 37 pertinent papers were retrieved. The findings from these studies suggest a SBP reduction of < 140 mm Hg for persons aged ≥ 60 years, with an attempt for SBP reduction to ≤130 mm Hg in healthier subjects and hose with CVD, DM, and CKD. Care should be taken not to further reduce the SBP in older subjects if their DBP is ≤60 mmHg for the fear of J-curve effect.

Entities:  

Keywords:  Systolic blood pressure; complications; older age; treatment targets

Mesh:

Substances:

Year:  2018        PMID: 29375010     DOI: 10.1080/00325481.2018.1433434

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  5 in total

Review 1.  Position statement on use of pharmacological combinations in a single pill for treatment of hypertension by Argentine Federation of Cardiology (FAC) and Argentine Society of Hypertension (SAHA).

Authors:  Nicolás Renna; Daniel Piskorz; Diego Stisman; Diego Martinez; Ludmila Lescano; Sergio Vissani; Walter Espeche; Diego Marquez; Roberto Parodi; Diego Naninni; Marcos Baroni; Daniel Llanos; Rocio Martinez; Jessica Barochinner; Gustavo Staffieri; Fernando Lanas; Mónica Velásquez; Marcos Marin; Bryan Williams; Irene Ennis
Journal:  J Hum Hypertens       Date:  2021-06-04       Impact factor: 3.012

Review 2.  Evidence-Based Management of Diabetes in Older Adults.

Authors:  Arshag D Mooradian
Journal:  Drugs Aging       Date:  2018-12       Impact factor: 3.923

3.  Orthostatic hypotension and cardiovascular outcomes: Should we be concerned?

Authors:  Steven G Chrysant
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-09-10       Impact factor: 3.738

4.  Association between control status of blood pressure and frailty among middle-aged and older adults with hypertension in China: a longitudinal study.

Authors:  Feifei Shen; Jiangyun Chen; Ruijing Yang; Jun Yang; Haomiao Li
Journal:  BMJ Open       Date:  2022-03-14       Impact factor: 2.692

5.  Effectiveness of blood pressure-lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).

Authors:  Ling Zhang; Xiuting Sun; Lizhen Liao; Shaozhao Zhang; Huimin Zhou; Xiangbin Zhong; Xiaodong Zhuang; Xinxue Liao
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-10-31       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.